Pharmacokinetic data can be used to calculate individualized dosage regimens for antiarrhythmic drugs to guide patient management and avoid toxicity.
May guide individualized antiarrhythmic dosing; leaves open prospective validation before clinical adoption.
Pharmacokinetic data presented in Part I of this paper are used to show how dosage regimens may be developed for antiarrhythmic drugs. Dosage regimen calculations are presented for intravenous infusion of lidocaine and for oral administration of procainamide and propranolol. Dosing flow charts are presented for lidocaine and procainamide. While dosage regimens could be calculated for diphenylhydantoin, there are no reliable data on the fraction of administered dose available systemically and the volume of distribution of the drug. Clinical conditions where average doses of antiarrhythmics will lead to toxic effects are discussed. The method of calculating dosage regimens is applicable to individual patient data and can serve as a useful guideline in managing patients.
No takes yet. Share an insight, caveat, or question.
René H. Levy (1973) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: